Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

Authors
Category Primary study
JournalEuropean Journal of Cancer
Year 2016
This article has no abstract
Epistemonikos ID: 4adbc7b3a11a82737ecac3f448d03c5fcc5b5946
First added on: Feb 08, 2025